Refractory palmoplantar pustulosis succesfully treated with apremilast

被引：7
作者：
de Lome, Raquel Carrascosa [1 ]
Montero, Elena Conde [1 ]
Dobao, Pablo de la Cueva [1 ]
机构：
[1] Hosp Univ Infanta Leonor, Dermatol Dept, Ave Gran Via Este 80, Madrid 28031, Spain
来源：
DERMATOLOGIC THERAPY | 2020年 / 33卷 / 02期
关键词：
inflammatory disorders; psoriasis; therapy-systemic; PHASE-III; INHIBITOR; PSORIASIS; EFFICACY; MODERATE;
D O I：
10.1111/dth.13230
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Palmoplantar pustulosis is a chronic inflammatory disease which characterized by a eruption of sterile pustules on the palms and soles. Apremilast is an oral phosphodiesterase-4 inhibitor which is approved for the treatment of chronic plaque psoriasis and psoriatic arthritis. However, no clinical trial has been performed to confirm the efficacy of apremilast for palmoplantar pustulosis yet. Moreover, there are very few cases of this disease treated with apremilast. Herein, we describe a case of a refractory palmoplantar pustulosis succesfully treated with apremilast.
引用
收藏
页数：2
相关论文
共 5 条
  • [1] Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis
    Bissonnette, Robert
    Pariser, David M.
    Wasel, Norman R.
    Goncalves, Joana
    Day, Robert M.
    Chen, Rongdean
    Sebastian, Michael
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (01) : 99 - 105
  • [2] Three cases of palmoplantar pustulosis successfully treated with apremilast
    Eto, Ayaka
    Nakao, Masayoshi
    Furue, Masutaka
    [J]. JOURNAL OF DERMATOLOGY, 2019, 46 (01) : E29 - E30
  • [3] Successful treatment of refractory palmoplantar pustulosis with apremilast
    Haebich, G.
    Kalavala, M.
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2017, 42 (04) : 471 - 473
  • [4] What do we know about palmoplantar pustulosis?
    Misiak-Galazka, M.
    Wolska, H.
    Rudnicka, L.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 38 - 44
  • [5] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
    Papp, Kim
    Reich, Kristian
    Leonardi, Craig L.
    Kircik, Leon
    Chimenti, Sergio
    Langley, Richard G. B.
    Hu, ChiaChi
    Stevens, Randall M.
    Day, Robert M.
    Gordon, Kenneth B.
    Korman, Neil J.
    Griffiths, Christopher E. M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (01) : 37 - 49
1